Puma Biotechnology Inc (PBYI) Stock Analysis

Puma Biotechnology Inc (PBYI) is a publicly traded company in the HEALTHCARE sector. It trades at $6.98, carries a market capitalization of $362.40M, a price-to-earnings ratio of 14.83. This page summarizes the public market data, fundamentals, and frequently asked questions for PBYI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Puma Biotechnology Inc currently has a Bullish sentiment score of 0.35.

About Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical firm based in Los Angeles that specializes in the development and commercialization of innovative cancer therapies aimed at enhancing treatment outcomes for patients globally. With a strong emphasis on precision medicine, Puma is advancing a proprietary pipeline of drug candidates targeting specific oncological indications, addressing crucial unmet needs in the oncology sector. The company's strategic positioning and commitment to innovation mak...

GNG Research Analysis

GNG Research scores Puma Biotechnology Inc (PBYI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PBYI.

Frequently Asked Questions

Does PBYI pay dividends?

Puma Biotechnology Inc (PBYI) does not currently pay a regular dividend.

What is PBYI's P/E ratio?

Puma Biotechnology Inc has a price-to-earnings (P/E) ratio of 14.83.

What is PBYI's market cap?

Puma Biotechnology Inc (PBYI) has a market capitalization of $362.40M with a current stock price of $6.98.